Terms: = Kidney tumors AND OMD, osteoadherin, 4958, ENSG00000127083, Q99983, SLRR2C
4 results:
1. Late metastatic presentation is associated with improved survival and delayed wide-spread progression after ablative stereotactic body radiotherapy for oligometastasis.
Chen X; Chen H; Poon I; Erler D; Badellino S; Biswas T; Dagan R; Foote M; Louie AV; Ricardi U; Sahgal A; Redmond KJ
Cancer Med; 2021 Sep; 10(18):6189-6198. PubMed ID: 34432390
[TBL] [Abstract] [Full Text] [Related]
2. Imaging and its Impact on Defining the Oligometastatic State.
Pirasteh A; Lovrec P; Pedrosa I
Semin Radiat Oncol; 2021 Jul; 31(3):186-199. PubMed ID: 34090645
[TBL] [Abstract] [Full Text] [Related]
3. Stereotactic radiotherapy combined with immunotherapy or targeted therapy for metastatic renal cell carcinoma.
Kroeze SGC; Fritz C; Schaule J; Siva S; Kahl KH; Sundahl N; Blanck O; Kaul D; Adebahr S; Verhoeff JJC; Skazikis G; Roeder F; Geier M; Eckert F; Guckenberger M
BJU Int; 2021 Jun; 127(6):703-711. PubMed ID: 33113260
[TBL] [Abstract] [Full Text] [Related]
4. [3D-technologies in planning and navigation for laparoscopic interventions in patients with renal and ureteric stones].
Alyaev YG; Sirota ES; Bezrukov EA; Ali SH
Urologiia; 2019 Sep; (4):9-15. PubMed ID: 31535798
[TBL] [Abstract] [Full Text] [Related]
